June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Clinical manifestations and visual prognosis of ocular toxoplasmosis
Author Affiliations & Notes
  • Joao M Furtado
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Brazil
  • Sigrid Arruda
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Brazil
  • Milena Simões
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Brazil
  • Denny Marcos Garcia
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Brazil
  • Michelle Araújo
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Brazil
  • Bárbara Vieira
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Brazil
  • Murilo Wendeborn Rodrigues
    Ophthalmology, University of Sao Paulo, Ribeirao Preto, Brazil
  • Justine Smith
    Flinders University, Adelaide, South Australia, Australia
  • Footnotes
    Commercial Relationships   Joao Furtado, None; Sigrid Arruda, None; Milena Simões, None; Denny Garcia, None; Michelle Araújo, None; Bárbara Vieira, None; Murilo Rodrigues, None; Justine Smith, None
  • Footnotes
    Support  Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FAEPA)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2175. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Joao M Furtado, Sigrid Arruda, Milena Simões, Denny Marcos Garcia, Michelle Araújo, Bárbara Vieira, Murilo Wendeborn Rodrigues, Justine Smith; Clinical manifestations and visual prognosis of ocular toxoplasmosis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2175.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe clinical aspects and visual outcomes in individuals with ocular toxoplasmosis in Brazil.

Methods : Individuals resident in Ribeirão Preto, Brazil who had serological evidence and clinical signs of ocular toxoplasmosis were included in this study. A uveitis specialist made the diagnosis of ocular toxoplasmosis from serological evidence of infection (T. gondii IgG and/or IgM positivity) and the presence of either focal retinitis or hyperpigmented retinochoroidal scars. The disease was defined as primary (active lesion in the absence of scars), recurrent active (active lesion in the presence of scars) or inactive (scars only). Atypical disease was included only when polymerase chain reaction revealed the presence of T. gondii DNA in aqueous humor. Subjects were examined by slit lamp and indirect ophthalmoscopy, and best corrected visual acuity (BCVA) was tested at all visits.

Results : One hundred sixty-three subjects (51% men and 49% women) were included in the study (n=212 eyes). Twenty-two subjects (13.5%) were ≤ 17 years of age; 125 subjects were 18-64 years of age; and 16 subjects (9.8%) were ≥65 years of age. The form of ocular toxoplasmosis was primary active in 23 subjects (14.1%), recurrent active in 42 subjects (25.8%) and inactive in 98 subjects (60.1%). Most subjects presented with a single lesion (n=110; 51.9%), but 75 individuals (35.4%) had 2-4 lesions, and 27 had ≥5 lesions (12.7%). Lesions were central in 74 eyes (35%), peripheral in 101 eyes (47.6%%), and central and peripheral in 37 eyes (17.5%). Only 3 individuals (1.8%) presented with atypical ocular disease. Most subjects had T. gondii IgG+ IgM- serology (n=153; 93.9%);10 subjects (6.1%) had T. gondii IgG+ IgM+ serology. From the total of 198 affected eyes in which visual acuity could be measured, most (n=111; 56%) had final BCVA ≤20/40, and 40.5% of eyes (n= 45) were legally blind (BCVA <20/200). Visual acuity could not be measured in 14 eyes (6.6%) of infants. Three individuals presented bilateral BCVA <20/200.

Conclusions : Ocular toxoplasmosis resulted in reduced vision in a significant number of individuals examined in this study. Prophylactic measures should be implemented for persons at high risk of vision loss from the disease, and the development of new therapeutic modalities should be a goal of future studies.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×